GlobeNewswire

Jumio Records Best Sales Quarter in Company History, Fueled by Q2 Growth in Asia Pacific

Dela

Jumio Records Best Sales Quarter in Company History, Fueled by Q2 Growth in Asia Pacific

Jumio's sales grew by more than 200 percent year over year for three of our last four quarters; the company has recorded quarter over quarter sales growth nine of the last ten quarters

PALO ALTO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Jumio, the leading AI-powered trusted identity as a service provider, today announced its best sales quarter in company history, ending June 30, 2018, representing a 269 percent increase in sales over the same quarter last year. The results were fueled by record sales growth in the Asia Pacific region, which grew 531 percent over the previous quarter.

"We're thrilled that within three months of opening our Singapore office, Asia Pacific has already generated so much in sales and has seen such wide adoption," said Steve Stuut, CEO of Jumio. "This type of immediate market traction speaks to the opportunity this region represents and the untapped potential, especially within financial services, enterprise and e-commerce markets."

The emerging need for reliable digital identity verification, coupled with increasingly stringent data protection and privacy regulations (e.g., GDPR and California Consumer Privacy Act) and the growing realization that traditional authentication methodologies are no longer effective or secure, has caused companies to explore the identity-verification-as-a-service market.

According to a market study by McKinsey, the emerging identity-verification-as-a-service market is close to $10 billion and predicts it will grow to a $16-20 billion market by 2022. McKinsey reports, "Identity verification-as-a-service offers a way for e-commerce providers to outsource the verification function to providers with the necessary scale and security to accomplish sensitive transactions quickly, safely, and efficiently." In fact, the Asia Pacific market is growing almost 50 percent faster than the North America and Western European markets because of the higher volume of digital transactions that require online identity verification.

Increased awareness and familiarity with identity verification has helped fuel Jumio's continued momentum as the company reports its strongest quarter in company history, including these notable milestones:

  • Six Straight Quarters of Sales Growth: Jumio grew sales nine of the past ten quarters, demonstrating growing traction for its online ID and identity verification solutions. Its focus on compliant machine learning, leading-edge identity proofing technologies, and a customer-centric mentality have helped Jumio set the bar for online identity verification accuracy and gain significant market share.
  • AsiaPac Expansion: In Q2, Jumio saw its Asia Pacific sales grow significantly and signed two of the largest deals in the company's history as a result of having a dedicated regional focus, which includes a new Singapore office and expanded sales presence to support the region's growing demand for online digital identity verification and Know Your Customer (KYC) services. 
  • Liveness Detection for Web: Jumio launched Liveness Detection for Web to ensure that the online user is physically present during the identity verification process when using their computer's webcam. This new functionality requires the user to take a picture of themself holding a handwritten note with a custom phrase (e.g. company name) and the current date, to ensure a real person is performing the transaction. 
  • Executive Hires: In Q2, Jumio hired several new executives to further strengthen its leadership team and support its aggressive growth objectives, including: Miles Hutchinson, Chief Information Security Officer; Mike O'Callaghan,Vice President Global Operations; and Amy Treadwell, Global Vice President of People and Culture. Together, the three new hires bring decades of leadership experience in high-growth SaaS and technology organizations.
  • Industry Recognition: Jumio continues to be recognized for its product innovation, including being awarded the Gold winner in Information Security and Risk Management (and Bronze winner for Security Software) in the 13th Annual 2018 IT World Awards®, named Best Product in Biometrics and Hot Company in Fraud Prevention by the 2018 InfoSec Awards, and named the winner in the Best Authentication Technology category by the 2018 SC Awards. Jumio was also included as a Representative Vendor in the "Market Guide for Identity Proofing and Corroboration," published by Gartner, a leading information technology research and advisory company.

For live demonstrations of the Netverify ID, Identity and Document Verification solutions, visit Jumio at the iGB Live show (Stand T7) this month in Amsterdam.

About Jumio
When identity matters, trust Jumio. Jumio is the creator of Netverify® which enables businesses to increase customer conversions while providing a seamless customer experience and reducing fraud. By combining the three core pillars of ID Verification, Identity Verification and Document Verification, businesses now have a complete solution that allows them to establish the real-world identity of the consumer.

Leveraging advanced technology including augmented AI, biometric facial recognition, machine learning, and human review, Jumio helps organizations to meet regulatory compliance including KYC, AML and GDPR and definitively establish the digital identity of their customers. Jumio has verified more than 120 million identities issued by over 200 countries from real time web and mobile transactions. Jumio's solutions are used by leading companies in the financial services, sharing economy, cryptocurrency, retail, travel and online gaming sectors. Based in Palo Alto, Jumio operates globally with offices in the US, Europe, and Asia Pacific and has been the recipient of numerous awards for innovation. For more information, please visit www.jumio.com.

Media Contacts
U.S. Media Contact
Jackie Daane
10Fold Communications
Jumio@10fold.com
415-800-5369

Europe Media Contact
Zarina Banu
FleishmanHillard Fishburn
zarina.banu@fhflondon.co.uk
+44 (0) 7775 557578

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d1c780f4-0c16-40b0-acea-f900be5545a4




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Jumio Corp. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum